Literature DB >> 1714947

The particle size of hepatitis C virus estimated by filtration through microporous regenerated cellulose fibre.

T Yuasa1, G Ishikawa, S Manabe, S Sekiguchi, K Takeuchi, T Miyamura.   

Abstract

To estimate the particle size of hepatitis C virus (HCV), a major causative agent of post-transfusion non-A, non-B hepatitis, we filtered plasma or serum samples through microporous cellulose fibres with different pore sizes. The amount of HCV particles in samples before and after filtration was determined by a quantitative reverse transcriptase polymerase chain reaction (PCR) method. Since there is no quantitative biological assay for HCV, except for that in chimpanzees, the HCV titre obtained from the PCR method was used in an equation constructed previously for application to filtration experiments with a flavivirus which is distantly related to HCV. The particle was estimated to be between 30 and 38 nm in diameter, although the possibility remained that larger HCV particles or HCV aggregates with a diameter of more than 39 nm might exist. Double-step filtration through microporous cellulose fibres with a pore size of 35 nm reduced the HCV content to below levels detectable by our PCR method, indicating that it is possible to eliminate HCV particles by simple filtration techniques.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1714947     DOI: 10.1099/0022-1317-72-8-2021

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  11 in total

Review 1.  Hepatitis C virus: molecular biology and genetic variability.

Authors:  C Bréchot
Journal:  Dig Dis Sci       Date:  1996-12       Impact factor: 3.199

2.  Effect of filtration on morphine and particle content of injections prepared from slow-release oral morphine tablets.

Authors:  Stuart McLean; Raimondo Bruno; Susan Brandon; Barbara de Graaff
Journal:  Harm Reduct J       Date:  2009-12-22

3.  Formation and intracellular localization of hepatitis C virus envelope glycoprotein complexes expressed by recombinant vaccinia and Sindbis viruses.

Authors:  J Dubuisson; H H Hsu; R C Cheung; H B Greenberg; D G Russell; C M Rice
Journal:  J Virol       Date:  1994-10       Impact factor: 5.103

4.  Variable ratio of hepatitis C virus RNA to viral core antigen in patient sera.

Authors:  Christian G Schüttler; Christine Thomas; Thomas Discher; Georg Friese; Jürgen Lohmeyer; Ralph Schuster; Stephan Schaefer; Wolfram H Gerlich
Journal:  J Clin Microbiol       Date:  2004-05       Impact factor: 5.948

5.  Expression of processed envelope protein of hepatitis C virus in mammalian and insect cells.

Authors:  Y Matsuura; S Harada; R Suzuki; Y Watanabe; Y Inoue; I Saito; T Miyamura
Journal:  J Virol       Date:  1992-03       Impact factor: 5.103

Review 6.  Virion assembly and release.

Authors:  Brett D Lindenbach
Journal:  Curr Top Microbiol Immunol       Date:  2013       Impact factor: 4.291

Review 7.  Immunopathology of hepatitis C.

Authors:  K M Chang; B Rehermann; F V Chisari
Journal:  Springer Semin Immunopathol       Date:  1997

8.  Efficacy, Safety, and Pharmacokinetics of a Novel Human Immune Globulin Subcutaneous, 20 % in Patients with Primary Immunodeficiency Diseases in North America.

Authors:  Daniel Suez; Mark Stein; Sudhir Gupta; Iftikhar Hussain; Isaac Melamed; Kenneth Paris; Amy Darter; Christelle Bourgeois; Sandor Fritsch; Heinz Leibl; Barbara McCoy; David Gelmont; Leman Yel
Journal:  J Clin Immunol       Date:  2016-08-31       Impact factor: 8.317

9.  Efficacy, safety, tolerability and pharmacokinetics of a novel human immune globulin subcutaneous, 20%: a Phase 2/3 study in Europe in patients with primary immunodeficiencies.

Authors:  M Borte; G Kriván; B Derfalvi; L Maródi; T Harrer; S Jolles; C Bourgeois; W Engl; H Leibl; B McCoy; D Gelmont; L Yel
Journal:  Clin Exp Immunol       Date:  2016-10-18       Impact factor: 4.330

10.  Development of a downstream process for the production of an inactivated whole hepatitis C virus vaccine.

Authors:  Keven Lothert; Anna F Offersgaard; Anne F Pihl; Christian K Mathiesen; Tanja B Jensen; Garazi Peña Alzua; Ulrik Fahnøe; Jens Bukh; Judith M Gottwein; Michael W Wolff
Journal:  Sci Rep       Date:  2020-10-01       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.